| Home Market Dynamics Sector Analysis Company Insights AI Investing Strategies Contact Us Login |
| Eli Lilly's recent advancements in product/service development are particularly highlighted by the strong sales of their weight-loss drug Zepbound and diabetes drug Mounjaro, showcasing successful innovation in response to market needs. The company's commitment to expanding access to their obesity drug and the promising pipeline of future products indicate robust growth expectations. Innovative products such as GLP-1s reinforce their market leadership in the obesity treatment sector, driving optimism among investors. Overall, the combination of strategic product launches and market expansion opportunities positions Eli Lilly favorably for future success. |
| The price action of Eli Lilly (LLY) is impacted by broad market risk appetite, sector price trend, company-specific performance and market structure. The trend sentiment at 1 is bullish. The market sentiment at 2.1 is extremely bullish. Trend sentiment measures the current trend of the stock price, and market sentiment reflects what market participants collectively think where the price will move next.LLY is likely to move up since both trend sentiment and market sentiment are positive. The positive sentiment force for sector is at 2.1, and the negative at 0 on 2025-11-22. The forces of Valuation Sentiment (5.6), Sentiment towards Fundamentals (4.7), Market Risk Appetite (1), Sector Price Trend (1), Stock Price Trend (1), Option Sentiment (0), and Price Level Sentiment (0) will drive up the price. The forces of and Price Level Sentiment (0) will drive down the price. The sentiment for Sector Price Trend is calculated based on the price trend of related sector ETF. The sentiment for Option Speculation is calculated from put/call ratio. The Risk Appetite is calculated from Bitcoin price trend. Price Level sentiment is positive when oversold, and negative when overbought. Valuation Sentiment, and Sentimentals towards Fundamentals are extracted from headlines and market commentary. All sentiment scores are normalized on a -10 - +10 scale. The price level reaches 100 at Bollinger upper band, and zero at lower band. |
| LLY | |||||||||||||
| Date | Attention | Price | Price Level | Change | SMA10 Trend | Trend Sentiment | Hourly Trend | Hourly StdDev | Market Sentiment | Action | P | Fund. | News Sentiment |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025-11-22 | 1%(0.4%) | 1 | 0.25% | 2.1 | 4.7 | 7.5 | |||||||
| 2025-11-21 | 2%(0.3%) | 1 | 0.25% | 2.2 | 4.2 | 7.3 | |||||||
| 2025-11-20 | 0%(0%) | 1 | 0.25% | 1.2 | 3.8 | -1 | |||||||
| 2025-11-19 | 0%(0%) | 1 | 0.25% | 1.1 | 3.5 | 7 | |||||||
| 2025-11-18 | 0%(0%) | 1 | 0.25% | 0.9 | 2.4 | -1 | |||||||
| 2025-11-17 | 0%(0%) | 1 | 0.25% | 1.5 | 2.7 | 7 | |||||||
| 2025-11-16 | 0%(0%) | 1 | 0.25% | 1.6 | 3.1 | 4 | |||||||
| 2025-11-15 | 0%(0%) | 1 | 0.25% | 1.4 | 3.2 | 4 | |||||||
| 2025-11-14 | 0%(0%) | 1 | 0.25% | 1.6 | 3.3 | 7 | |||||||
| 2025-11-13 | 0%(0%) | 1 | 0.25% | 1.6 | 3.3 | -1 | |||||||
| Wait action is recommended in three scenarios with either high uncertainty or high risk: 1. The trend sentiment and market sentiment are at the opposite directions. 2. Both trend sentiment and market sentiment are positive, but the price level is elevated. 3. Both trend sentiment and market sentiment are negative, but the price level is depressed. In an uptrend, as an investor, you may want to wait for the pullback to open long position. In a downtrend, the price will likely rebound after huge decline. As an investor, you may want to wait for the rebound to exit long position. | |||||||||||||
| Market sentiment will accelerate the current trend when both trend sentiment and market sentiment are at the same direction. Market sentiment will generate volatility when it's at the opposite direction of the trend sentiment. News sentiment measures the daily emotion of the market. News sentiment may impact the daily price change while market sentiment is a more stable and consistent moving force. | |||||||||||||
| 2025-11-22 17:47:02 The overall growth of the GLP-1 market indicates a positive industry trend, showcasing the increasing demand for such medications. |
| 2025-11-22 17:47:02 The reference to GLP-1s suggests that Eli Lilly is successfully developing and marketing innovative products that have driven growth. |
| 2025-11-22 17:47:02 Eli Lilly achieving a trillion dollar market cap highlights its significant market success and the positive impact of its products. |
| 2025-11-22 17:02:08 Eli Lilly's solid earnings growth and raised full-year guidance underscore its positive outlook and sustained growth trajectory in the coming years. |
| 2025-11-22 17:02:08 Eli Lilly is positioned as a defensive option in the market, with its strong performances and guidance revisions appealing to investors during volatile market periods. |
| 2025-11-22 17:02:08 Several institutional investors have reduced their stakes in Eli Lilly, indicating a cautious approach amid changing market conditions while still tracking the company's performance. |
| 2025-11-22 17:02:08 Eli Lilly's leadership in the obesity treatment market is a key driver for revenue growth, with the potential for further expansion through innovative product offerings. |
| 2025-11-22 17:02:08 Eli Lilly has achieved a significant milestone by becoming the first health-care company to reach a $1 trillion market value, highlighting its strong stock performance and market presence. |
| 2025-11-22 11:47:44 Eli Lilly's pipeline of upcoming products is seen as promising, contributing to optimism about future growth and revenue. |
| 2025-11-22 11:47:44 The growth in stock value is attributed to positive expectations surrounding its products Mounjaro and Zepbound, showcasing the potential of its product pipeline. |
| 2025-11-22 11:47:44 Eli Lilly has achieved a significant milestone, surpassing a market capitalization of $1 trillion, indicating robust stock performance and investor confidence. |